Previous Close | 3.65 |
Open | 3.60 |
Bid | 3.50 x 1500 |
Ask | 3.85 x 1000 |
Day's Range | 3.45 - 3.75 |
52 Week Range | 2.80 - 13.05 |
Volume | 195,162 |
Avg. Volume | 461,411 |
Market Cap | 168.438M |
Beta | 2.15 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.75 |
Earnings Date | May 15, 2018 - May 21, 2018 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 12.00 |
Immune Design (IMDZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, April 02, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
The most recent earnings update Immune Design Corp’s (NASDAQ:IMDZ) released in December 2017 signalled that losses became smaller relative to the prrior year’s level – great news for investors Below,Read More...
Development of key pipeline candidates CMB305 and G100 is likely to keep Immune Design (IMDZ) on a growth trajectory.
Immune Design (IMDZ) reports narrower-than-expected loss in fourth quarter 2017 results and updates data for its pipeline candidates.
Q4 2017 Immune Design Corp Earnings Call
The Seattle-based company said it had a loss of 29 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a ...
-New positive clinical and translational data for both lead agents. -Strong balance sheet with 2017 year-end cash and equivalents of $144.2 Million. -Conference call at 1:30 pm Pacific today.
Assessing Immune Design Corp’s (NASDAQ:IMDZ) past track record of performance is a valuable exercise for investors. It enables us to reflect on whether the company has met or exceed expectations,Read More...
Median overall survival of 23.7 months following CMB305 monotherapy represents approximately one-year extension of survival compared to published data in soft tissue sarcoma patient population Objective ...
SEATTLE and SOUTH SAN FRANCISCO, Calif., March 07, 2018-- Immune Design, an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report fourth quarter and ...
We expect Immune Design (IMDZ) to shed light on the progression of the trails on pipeline candidates when it releases fourth-quarter earnings results on Mar 6.
Immune Design and Westlake Chemical Partners are a few noticeable companies with a strong future outlook. The market’s optimistic sentiment towards these stocks indicates a level of confidence in theRead More...
SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 09, 2018-- Immune Design, an immunotherapy company focused on next-generation therapies in oncology, today announced that senior management will present at ...
NEW YORK, Jan. 30, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Immune ...
Immune Design (IMDZ) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Immune Design Corp. Here are 5 ETFs with the largest exposure to IMDZ-US. Comparing the performance and risk of Immune Design Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Immune Design (IMDZ) needs investors to pay close attention to the stock based on moves in the options market lately.
Investors in Immune Design (IMDZ) need to pay close attention to the stock based on moves in the options market lately.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Immune Design Corp. Here are 5 ETFs with the largest exposure to IMDZ-US. Comparing the performance and risk of Immune Design Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)